Compass Therapeutics, Inc. (CMPX)

1.0000 -0.2000 (-16.67%) 收市：04:00PM EDT

Compass Therapeutics, Inc.

80 Guest Street
Suite 601
Boston, MA 02135
United States
(617) 500-8099
https://www.compasstherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 32

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Thomas J. Schuetz M.D., Ph.D.	Chief Executive Officer	835.88k	無	1961
Dr. Vered Bisker-Leib M.D., MBA, Ph.D.	Senior Consultant	719k	無	1971
Mr. Neil L. Lerner CPA	Vice President of Finance	無	無	1967
Mr. Jonathan Anderman J.D.	VP, Head of Legal & Corporate Secretary	無	無	無
Anna Gifford	Communications Manager	無	無	無
Dr. Minori Rosales M.D., Ph.D.	Senior VP & Head of Clinical Development	無	無	1963
Ms. Karin Herrera B.A.	VP & Head of Clinical Operations	無	無	無
Dr. James Kranz Ph.D.	VP and Head of Chemistry Manufacturing & Controls	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

公司管治

截至 2024年6月1日 止，Compass Therapeutics, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：3；董事會：7；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。